Balance Sheet

Cash Flow Statement

Amortization Amortization Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Legend Biotech (LEGN) Free Cash Flow (2019 - 2025)

Legend Biotech filings provide 7 years of Free Cash Flow readings, the most recent being -$12.2 million for Q4 2025.

On a quarterly basis, Free Cash Flow rose 88.7% to -$12.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$84.0 million, a 46.91% increase, with the full-year FY2025 number at -$100.2 million, up 36.62% from a year prior.
Free Cash Flow hit -$12.2 million in Q4 2025 for Legend Biotech, down from $33.8 million in the prior quarter.
In the past five years, Free Cash Flow ranged from a high of $33.8 million in Q3 2025 to a low of -$156.3 million in Q4 2021.
Median Free Cash Flow over the past 5 years was -$49.8 million (2021), compared with a mean of -$53.3 million.
Biggest five-year swings in Free Cash Flow: tumbled 8513.94% in 2023 and later surged 145.83% in 2025.
Legend Biotech's Free Cash Flow stood at -$156.3 million in 2021, then skyrocketed by 81.56% to -$28.8 million in 2022, then crashed by 356.25% to -$131.5 million in 2023, then increased by 17.9% to -$107.9 million in 2024, then surged by 88.7% to -$12.2 million in 2025.
The last three reported values for Free Cash Flow were -$12.2 million (Q4 2025), $33.8 million (Q3 2025), and -$3.8 million (Q2 2025) per Business Quant data.